G
Giuseppe Opocher
Researcher at University of Padua
Publications - 205
Citations - 11388
Giuseppe Opocher is an academic researcher from University of Padua. The author has contributed to research in topics: Aldosterone & Paraganglioma. The author has an hindex of 49, co-authored 204 publications receiving 10439 citations. Previous affiliations of Giuseppe Opocher include University of Turin.
Papers
More filters
Journal ArticleDOI
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
Hartmut P. H. Neumann,Christian Pawlu,Mariola Pęczkowska,Birke Bausch,Sarah R. McWhinney,Mihaela Muresan,Mary Buchta,Gerlind Franke,Joachim Klisch,Thorsten A. Bley,Stefan Hoegerle,Carsten Christof Boedeker,Giuseppe Opocher,Jörg Schipper,Andrzej Januszewicz,Charis Eng +15 more
TL;DR: In this article, the differences in clinical features in carriers of SDHB mutations and SDHD mutations were determined in a population-based genetic screening for Paraganglioma syndromes type 4 and type 1 (PGL-1), respectively.
Journal ArticleDOI
A Survey on Adrenal Incidentaloma in Italy
Franco Mantero,Massimo Terzolo,Giorgio Arnaldi,Giangiacomo Osella,Anna Maria Masini,A. Alì,Marilena Giovagnetti,Giuseppe Opocher,Alberto Angeli +8 more
TL;DR: A national survey on occasionally discovered adrenal masses under the auspices of the Italian Society of Endocrinology, which includes 1096 cases collected in 26 centers between 1980 and 1995, concluded that 85% of the masses were nonhypersecretory and 9.2% were defined as subclinical Cushing’s syndrome.
Journal ArticleDOI
A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.
Franco Mantero,Massimo Terzolo,Giorgio Arnaldi,Giangiacomo Osella,A. M. Masini,A. Alì,M. Giovagnetti,Giuseppe Opocher,Alberto Angeli +8 more
TL;DR: Results indicate that mass size is the most reliable variable in separating benign from malignant AI and Adrenalectomy should be recommended for AI greater than 4.0 cm because of the increased risk of malignancy, especially in young patients.
Journal ArticleDOI
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
Iñaki Comino-Méndez,Francisco Javier Gracia-Aznarez,Francesca Schiavi,Iñigo Landa,Luis J Leandro-García,Rocío Letón,Emiliano Honrado,Rocío Ramos-Medina,Daniela Caronia,Guillermo Pita,Álvaro Gómez-Graña,Aguirre A. de Cubas,Lucía Inglada-Pérez,Agnieszka Maliszewska,Elisa Taschin,Sara Bobisse,Giuseppe Pica,Paola Loli,Rafael Hernández-Lavado,José Ángel Díaz,Mercedes Gómez-Morales,Anna González-Neira,Giovanna Roncador,Cristina Rodríguez-Antona,Javier Benitez,Massimo Mannelli,Giuseppe Opocher,Mercedes Robledo,Alberto Cascón +28 more
TL;DR: The involvement of the MYC-MAX-MXD1 network in the development and progression of neural crest cell tumors is supported and the lack of functional MAX in rat PCC (PC12) cells is supported, which suggests that loss of MAX function is correlated with metastatic potential.
Journal ArticleDOI
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Yuejuan Qin,Li Qin Yao,Elizabeth E. King,Kalyan Buddavarapu,Romina E. Lenci,E. Sandra Chocron,James D. Lechleiter,Meghan B. Sass,Neil Aronin,Francesca Schiavi,Francesca Boaretto,Giuseppe Opocher,Rodrigo A. Toledo,Sergio P. A. Toledo,Charles D. Stiles,Ricardo C.T. Aguiar,Patricia L. M. Dahia +16 more
TL;DR: The studies identify TMEM127 as a tumor suppressor gene and validate the power of hereditary tumors to elucidate cancer pathogenesis, as well as identifying the transmembrane-encoding gene TMEM 127 as a negative regulator of mTOR.